Request availability and a quotation for your required quantity and destination.
| Product | Semaglutide 0.25 mg - Wegovy Pen |
|---|---|
| Categories | Weight Loss |
| Availability | Confirmed on enquiry |
Product listing is not a recommendation to use this medicine. Prescription and destination requirements apply where relevant.
Active ingredient: Semaglutide
Strength: 0.25 mg
Dosage form: Subcutaneous injection pen
Medicine class: GLP-1 receptor agonist
Prescription status: Prescription medicine
Wegovy 0.25 mg contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist used as part of medically supervised chronic weight management in eligible patients, together with dietary and physical-activity measures. The 0.25 mg strength is an initiation dose used at the beginning of dose escalation and is not the usual maintenance strength. Eligibility and dosing should be determined by a qualified healthcare professional according to the approved indication in the patient’s country.
Wegovy is prescribed for chronic weight management in eligible people with obesity, or overweight with relevant weight-related health conditions, subject to the approved indication and local clinical guidance. Treatment is intended to complement—not replace—appropriate nutrition, physical activity and ongoing medical care.
Semaglutide acts on GLP-1 receptors involved in appetite and energy-intake regulation. It can increase feelings of fullness and reduce hunger and calorie intake. Individual response varies, and treatment should be assessed as part of a broader weight-management plan.
Yes. The 0.25 mg strength is generally used at the start of Wegovy treatment. Dose escalation is gradual to improve gastrointestinal tolerability. Patients should follow their prescriber’s schedule and should not increase the dose early or switch strengths without medical advice.
Wegovy is administered by subcutaneous injection according to the instructions supplied with the specific pen. Patients should receive appropriate instruction on injection technique, dosing and storage. Do not share injection pens or needles.
Semaglutide is not appropriate for every patient. A prescriber should review medical history, pregnancy plans and other medicines before treatment. Important risks and precautions can include gastrointestinal adverse effects, pancreatitis, gallbladder problems, dehydration-related kidney injury, hypoglycaemia when combined with certain diabetes medicines, and other product-specific warnings.
Patients should seek medical attention for severe or persistent abdominal pain, serious allergic-reaction symptoms, or other significant or unexpected symptoms. Semaglutide products should not be combined or switched without professional guidance.
Gastrointestinal effects such as nausea, vomiting, diarrhoea, constipation and abdominal discomfort are commonly associated with semaglutide treatment, particularly during dose escalation. A healthcare professional should be consulted if symptoms are severe, persistent or causing dehydration.
Patients researching the Wegovy dose-escalation pathway can also view Wegovy 0.5 mg, Wegovy 1 mg, Wegovy 1.7 mg and Wegovy 2.4 mg. These links are for product information and do not imply that a patient should move to another strength without a prescriber’s direction.
For educational comparison, Cureiva also lists liraglutide – Saxenda Pen, tirzepatide 2.5 mg – Mounjaro KwikPen and orlistat 120 mg – Orligal. These medicines differ in mechanism, indications, dosing, contraindications and regulatory status and should not be treated as interchangeable.
For independent clinical information, see the NICE guidance on semaglutide for managing overweight and obesity and current official prescribing/product information applicable in your country. Cureiva’s product information is educational and does not replace the manufacturer’s leaflet or advice from a qualified healthcare professional.
It is the introductory Wegovy strength used when eligible patients begin semaglutide treatment for chronic weight management under medical supervision.
No. It is generally an initiation dose in the dose-escalation schedule. The appropriate maintenance dose is determined by the prescriber and applicable product guidance.
Wegovy is generally administered once weekly. Patients should follow the exact schedule and instructions supplied with their prescribed product.
Response varies between individuals. Weight management is assessed over time rather than after a single injection, and early treatment includes gradual dose escalation. A clinician should assess response, tolerability and whether ongoing treatment remains appropriate.
Both contain semaglutide, but they are marketed with different approved indications, dose regimens and product presentations depending on the country. They should not be treated as automatically interchangeable.
Wegovy contains semaglutide, while Mounjaro contains tirzepatide. They act through different incretin-receptor pathways and have different approved indications and dosing schedules depending on jurisdiction. A clinician should determine which treatment, if any, is appropriate.
Do not change the prescribed escalation schedule without medical advice. Gradual escalation is used partly to improve tolerability.
Yes. Cureiva Healthcare accepts international product enquiries. Availability, prescription requirements, cold-chain considerations where applicable, and personal-import rules depend on the destination country and individual request.
Related educational guide: Wegovy, Ozempic and Rybelsus: differences and approved uses. Indications and available strengths vary by country; this guide does not replace prescribing information or clinical review.
Cureiva Healthcare provides product information and handles international enquiries subject to prescription requirements, destination-country regulations and availability. Product information on this page is not a diagnosis or personal treatment recommendation.
Medical content standard: Information is prepared from established product and clinical guidance and should be checked against current official prescribing information before treatment decisions.
Last content review: October 2026